Dr. Jasgit Sachdev, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $19,644 | 7 | 54.0% |
| Unspecified | $6,283 | 5 | 17.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,779 | 4 | 13.1% |
| Travel and Lodging | $3,214 | 7 | 8.8% |
| Food and Beverage | $2,425 | 40 | 6.7% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $9,915 | 13 | $0 (2020) |
| Ipsen Bioscience Inc | $6,793 | 6 | $0 (2019) |
| F. Hoffmann-La Roche AG | $5,024 | 5 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $4,831 | 3 | $0 (2021) |
| Celgene Corporation | $2,833 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $2,278 | 8 | $0 (2019) |
| Roche Products Limited | $1,545 | 3 | $0 (2018) |
| Immunomedics, Inc. | $1,300 | 1 | $0 (2020) |
| Puma Biotechnology, Inc. | $1,140 | 3 | $0 (2018) |
| Foundation Medicine, Inc. | $229.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $264.69 | 3 | Foundation Medicine, Inc. ($229.00) |
| 2021 | $1,382 | 2 | AstraZeneca Pharmaceuticals LP ($1,370) |
| 2020 | $9,495 | 5 | AstraZeneca Pharmaceuticals LP ($3,450) |
| 2019 | $13,243 | 16 | Ipsen Bioscience Inc ($6,793) |
| 2018 | $8,676 | 24 | F. Hoffmann-La Roche AG ($3,479) |
| 2017 | $3,296 | 14 | Celgene Corporation ($2,819) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/23/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: ONC | ||||||
| 06/05/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Food and Beverage | In-kind items and services | $229.00 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: ONC | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/13/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $776.74 | Research |
| Study: GDC0032 Ph I II Solid Tumors and Breast Cancer • Category: None | ||||||
| 12/17/2020 | Immunomedics, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: Oncology | ||||||
| 12/16/2020 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Non-Covered Product (Drug) | — | In-kind items and services | $768.45 | Research |
| Study: AN OPEN-LABEL, PHASE III, DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC 0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN'S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER • Category: None | ||||||
| 06/23/2020 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| 12/12/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.60 | General |
| 10/28/2019 | PFIZER INTERNATIONAL LLC | — | Consulting Fee | Cash or cash equivalent | $4,818.75 | General |
| 09/11/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $643.42 | General |
| 09/11/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $280.62 | General |
| 09/11/2019 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $249.00 | General |
| 09/11/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $110.15 | General |
| 06/01/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $171.91 | General |
| 04/25/2019 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $91.77 | General |
| Category: ONCOLOGY | ||||||
| 02/12/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $31.61 | General |
| 02/07/2019 | Ipsen Bioscience Inc | ONIVYDE (Drug) | Consulting Fee | Cash or cash equivalent | $5,880.00 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Ipsen Bioscience Inc | ONIVYDE (Drug) | Travel and Lodging | In-kind items and services | $597.60 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Ipsen Bioscience Inc | ONIVYDE (Drug) | Travel and Lodging | In-kind items and services | $152.10 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Ipsen Bioscience Inc | ONIVYDE (Drug) | Food and Beverage | In-kind items and services | $80.36 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Ipsen Bioscience Inc | ONIVYDE (Drug) | Food and Beverage | In-kind items and services | $45.81 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| CC-486-BRSTM-001 | Celgene Corporation | $1,488 | 1 |
| GDC0032 Ph I II Solid Tumors and Breast Cancer | F. Hoffmann-La Roche AG | $776.74 | 1 |
| AN OPEN-LABEL, PHASE III, DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC 0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS OR NON-HODGKIN'S LYMPHOMA AND IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER | F. Hoffmann-La Roche AG | $768.45 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 42 | 56 | $18,500 | $4,686 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $6,552 | $1,745 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 31 | $7,316 | $1,707 | 23.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $4,632 | $1,234 | 26.6% |
About Dr. Jasgit Sachdev, M.D
Dr. Jasgit Sachdev, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Tempe, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1770706632.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jasgit Sachdev, M.D has received a total of $36,357 in payments from pharmaceutical and medical device companies, with $264.69 received in 2022. These payments were reported across 64 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($19,644).
As a Medicare-enrolled provider, Sachdev has provided services to 42 Medicare beneficiaries, totaling 56 services with total Medicare billing of $4,686. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Tempe, AZ
- Active Since 04/10/2007
- Last Updated 06/14/2011
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1770706632
Products in Payments
- ONIVYDE (Drug) $6,793
- Non-Covered Product (Drug) $3,090
- KISQALI (Drug) $2,141
- CC-486 (Drug) $1,488
- LYNPARZA (Drug) $1,370
- Trodelvy (Drug) $1,336
- Abraxane (Drug) $1,331
- Nerlynx (Drug) $1,140
- FOUNDATIONONE CDX (Device) $229.00
- Herceptin (Biological) $139.49
- IBRANCE (Drug) $104.79
- PIQRAY (Drug) $91.77
- VARUBI (Drug) $25.80
- OPDIVO (Biological) $21.66
- SANCUSO (Drug) $18.35
- SUBSYS (Drug) $15.26
- Lazanda (Drug) $14.22
- RELISTOR ORAL (Drug) $14.03
- AKYNZEO (Drug) $11.26
- MOVANTIK (Drug) $11.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Tempe
Julie Linn
Student in an Organized Health Care Education/Training Program — Payments: $5,473
Kara Shieh
Student in an Organized Health Care Education/Training Program — Payments: $2,342
Dr. Anthony Canestraro, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $1,888
Adam Myers-White, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $1,663
Dr. Hermina Fernandes, Mbbs, Facp, MBBS, FACP
Student in an Organized Health Care Education/Training Program — Payments: $1,115
Dr. Joshua Pittman, Do, DO
Student in an Organized Health Care Education/Training Program — Payments: $1,041